All Moderna articles
-
NewsKorea University College of Medicine Vaccine Innovation Center selected to lead KDCA-funded hantavirus vaccine development project
The Vaccine Innovation Center at Korea University College of Medicine has been selected by the Korea Disease Control and Prevention Agency (KDCA) as the lead institution for a national hantavirus vaccine development project.
-
NewsmRNA flu vaccine offers immune protection against wide array of influenza virus strains
A new study has found that an investigational mRNA influenza vaccine helps the immune system recognize a wider range of influenza viruses than today’s standard flu shot, offering stronger and potentially longer-lasting protection. The vaccine, developed by Moderna, is currently under review by the U.S. Food and Drug Administration.
-
News CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates
The Coalition for Epidemic Preparedness Innovations (CEPI) will urgently accelerate development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda.
-
NewsGlobal Virus Network statement on H5N1 vaccine developments
The new vaccine momentum reflects the growing urgency of avian influenza (H5N1) threat and reinforces the need for coordinated global preparedness.
-
NewsBooster jabs reduce the risks of COVID-19 deaths, study finds
Booster vaccines reduced the risk of COVID‑19–related hospitalisation and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England.
-
NewsKorea University Vaccine Innovation Center teams with Moderna on mRNA-based hantavirus vaccine development
The Vaccine Innovation Center at Korea University College of Medicine has entered into a full-scale collaboration with global pharmaceutical company Moderna to develop an mRNA-based hantavirus vaccine.
-
NewsInvestigational mpox mRNA vaccine reduces disease severity in primates compared to available vaccines
A new mpox vaccine candidate more effectively limits symptoms and disease duration in primates that were infected with a lethal strain of the mpox virus when compared to a currently licensed modified vaccinia Ankara (MVA) vaccine.
-
NewsVaccine shows promise against CMV, a virus that causes birth defects
An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV vaccine candidate, a study reveals.
-
NewsVulnerability to different COVID-19 mutations depends on previous infections and vaccination
A person’s immune response to variants of SARS-CoV-2 depends on their previous exposure – and differences in the focus of immune responses will help scientists understand how to optimise vaccines in the future to provide broad protection.
-
NewsModerna is safest, most effective mRNA vaccine against COVID-19 for older adults
A study of older US adults found that the risk of negative effects of both mRNA vaccines is exceptionally low, but lowest with the Moderna vaccine.
-
NewsCovid-19 jab shows no serious side effects in young children
A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children - most of them aged 4 and younger - found no indications of serious side effects.